Rumor Mill: Pfizer eyeing MediGene

Rumors are swirling that Pfizer is looking to take over the German biotech MediGene. Shares of the smaller company leapt more than 12 percent today as reports of a possible deal hit the newswires. Neither company would comment on whether they've held talks, as reports suggest.

MediGene specializes in cancer, autoimmune disease, and skin disease; its two marketed products are the prostate cancer treatment Eligard and a genital warts med Veregen. European approval for a skin drug, Oracea, is pending. In the pipeline: A pancreatic cancer drug, Endotag.

- see the story in Forbes
- check out the brief at Thomson Merger News

Related Articles:
Woe is Pfizer, analysts say
Pfizer suffers as big drugs falter
Pfizer's Kindler can't quash mega-deal talk
Analysts not impressed with Pfizer
MediGene to buy UK's Avidex